Some of those events, include: RAS mutations (25% in poorly differentiated thyroid cancers); activating mutations of PIK3CA; point mutation p.V600E in BRAF; mutations in CTNNB1 (β-catenin) which is involved in Wnt signaling, and in TP53 (a tumor suppressor), which may participate in de-differentiation of these tumors [116,117]. Here, BRAF is linked to thyroid cancer.